Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Takeda Pharmaceutical's LIOVEL new drug application (NDA).
Subscribe to our email newsletter
LIOVEL is a combined fixed dose tablet of NESINA and ACTOS.
NESINA (alogliptin) and Actos (pioglitazone Hcl) are indicated for a treatment of type 2 diabetes.
LIOVEL is a tablet taken orally once daily and has two dosage strengths, ‘LIOVEL LD’ and ‘LIOVEL HD’ which contain 25mg alogliptin /15mg pioglitazone, and 25mg alogliptin /30mg pioglitazone respectively.
Takeda Pharma Development Division general manager said LIOVEL is expected to provide benefit to patients by improving glucose control along with greater ease of administration due to the combination of these two medications.